Literature DB >> 12439039

Prospective study of indwelling central venous catheter-related complications in children with broviac or clampless valved catheters.

Giuseppe Fratino1, Angelo C Molinari, Cinzia Mazzola, Mareva Giacchino, Paola Saracco, Evelina Bertocchi, Elio Castagnola.   

Abstract

PURPOSE: To compare two types of central venous catheters (Broviac and valved clampless) for the incidence and severity of catheter-related complications in children. PATIENTS AND METHODS: The authors report data on the mechanical and infectious complications collected in a prospective analysis of 92 catheters inserted in 82 children from January 2000 to March 2001.
RESULTS: Two different devices were inserted: 51 Broviac and 41 clampless valved catheters. During the follow-up of 17,803 catheter-days 52 complications were observed: 40 mechanical episodes and 12 infectious events. In the Broviac group the median follow-up was 179 days and the total number of catheter-days was 10,911. A total of 29 complications were observed, occurring in 22 catheters (43%), with an overall incidence of 0.27/100 catheter-days. In the clampless group the median follow-up was 134 days and the total number of catheter days was 6893. A total of 23 complications were observed, occurring in 19 devices (46%), with an incidence of 0.32/100 catheter days.
CONCLUSIONS: There were no major differences in the incidence of mechanical or infectious complications between the two devices. Malfunction was more frequent in Broviac catheters, whereas catheter displacement occurred more frequently in clampless valved catheters. These results show the importance of central venous catheter-related mechanical complications in the management of children with hematologic or oncologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439039     DOI: 10.1097/00043426-200211000-00011

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  7 in total

Review 1.  Catheter-related infections in pediatric patients with cancer.

Authors:  V Cecinati; L Brescia; L Tagliaferri; P Giordano; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-03       Impact factor: 3.267

2.  A prospective 7-year survey on central venous catheter-related complications at a single pediatric hospital.

Authors:  M Pinon; S Bezzio; P A Tovo; F Fagioli; L Farinasso; R Calabrese; M Marengo; M Giacchino
Journal:  Eur J Pediatr       Date:  2009-03-17       Impact factor: 3.183

3.  Incidence of indwelling central venous catheter-related complications using the Sri Paran technique for device fixation in children with cancer.

Authors:  G Fratino; S Avanzini; A C Molinari; P Buffa; E Castagnola; R Haupt
Journal:  Pediatr Surg Int       Date:  2009-06-12       Impact factor: 1.827

Review 4.  Innovative parenteral and enteral nutrition therapy for intestinal failure.

Authors:  Hau D Le; Erica M Fallon; Vincent E de Meijer; Alpin D Malkan; Mark Puder; Kathleen M Gura
Journal:  Semin Pediatr Surg       Date:  2010-02       Impact factor: 2.754

5.  A single institution observational study of early mechanical complications in central venous catheters (valved and open-ended) in children with cancer.

Authors:  Giuseppe Fratino; Elio Castagnola; Claudio Carlini; Cinzia Mazzola; Vincenzo Jasonni; Angelo Claudio Molinari; Riccardo Haupt
Journal:  Pediatr Surg Int       Date:  2004-09-24       Impact factor: 1.827

6.  Urokinase for restoring patency of malfunctioning or blocked central venous catheters in children with hemato-oncological diseases.

Authors:  Angelo Claudio Molinari; Riccardo Haupt; Paola Saracco; Maria Di Marco; Elio Castagnola; Giuseppe Fratino
Journal:  Support Care Cancer       Date:  2004-09-09       Impact factor: 3.603

7.  Factors affecting mechanical complications of central venous access devices in children.

Authors:  Jessica J Zhang; Ramesh M Nataraja; Amiria Lynch; Richard Barnes; Peter Ferguson; Maurizio Pacilli
Journal:  Pediatr Surg Int       Date:  2022-05-05       Impact factor: 2.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.